COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

UltraShape Power in Combination With U-sculpt-n Transducer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02956720
Recruitment Status : Unknown
Verified July 2017 by Ronen Glesinger, Syneron Candela.
Recruitment status was:  Recruiting
First Posted : November 6, 2016
Last Update Posted : August 1, 2017
Information provided by (Responsible Party):
Ronen Glesinger, Syneron Candela

Brief Summary:
Prospective, open label, self - controlled, single arm, clinical study to assess the performance of the UltraShape Power using the U-Sculpt-N on outer thigh and/or flank for circumference reduction versus self-control.

Condition or disease Intervention/treatment Phase
Circumference Reduction Device: UltraShape Power Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: prospective, single arm
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Evaluation of UltraShape Power System in Conjunction With the U-Sculpt-N Transducer for Non-invasive Circumference Reduction
Actual Study Start Date : January 2017
Estimated Primary Completion Date : May 2018
Estimated Study Completion Date : October 2018

Arm Intervention/treatment
Experimental: single arm Device: UltraShape Power
non-invasive body contouring procedure

Primary Outcome Measures :
  1. Outer thigh circumference reduction [ Time Frame: up to 24 week ]
    To evaluate circumference reduction of outer thigh post treatment with UltraShape Power device used with the U-Sculpt-N transducer versus control side.

  2. Treatment-related adverse events [ Time Frame: up to 24 week ]
    The frequency and severity of all treatment-related adverse events during and after using the UltraShape Power device used with the U-Sculpt-N transducer.

Secondary Outcome Measures :
  1. Subject satisfaction questionnaire [ Time Frame: up to 24 week ]
    The assessment of subject satisfaction with treatment will be recorded during relevant visits (starting following the first treatment) using a 5-point Likert scale

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Subject ≥18 and ≤60 years of age at the time of enrollment
  2. Fat thickness of at least 1.5 cm in the outer thigh and/or flank (measured by calibrated caliper)
  3. For women of child-bearing potential: negative urine pregnancy test
  4. General good health confirmed by medical history and skin examination of the treated area
  5. Subject understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed.

Exclusion Criteria:

  1. History of un-balanced hypertension, ischemic heart disease, valvular heart disease, congestive heart failure, pacemaker/defibrillator
  2. Current hyperlipidemia, diabetes mellitus, hepatitis, liver disease, HIV positive status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue disease
  3. Having a permanent implant in the treated area, such as metal plates, or an injected chemical substance such as silicone
  4. Previous liposuction in the treatment areas within 12 months
  5. History of skin disease in the treatment area, known tendency to form keloids or poor wound healing
  6. Abnormal kidney, liver or coagulation functions, abnormal lipid profile or blood count within the last 3 months
  7. Childbirth within the last 12 months or women who are breastfeeding a child

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02956720

Layout table for location contacts
Contact: Ketty Shkolnik, Ph.D. +972-73-2442268

Layout table for location information
Beit Noah Recruiting
Ramat Gan, Israel
Contact: Ronen Glesinger, Dr         
Sponsors and Collaborators
Syneron Candela
Layout table for additonal information
Responsible Party: Ronen Glesinger, Principal investigator, Syneron Candela Identifier: NCT02956720    
Other Study ID Numbers: DHF21321
First Posted: November 6, 2016    Key Record Dates
Last Update Posted: August 1, 2017
Last Verified: July 2017